About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.Stay Connected
My Profile
I am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
April 2024 M T W T F S S 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Twitter List
Legislative Tracking Tools
Category Archives: Podcast
FDA Pioneers New Level of Transparency – An Interview with Dr. Joshua Sharfstein
No kidding. I mean it. Transparency is one of those buzz words that doesn't really mean much to people, because it means so many things to so many people. As a result, in some ways, the word has lost its … Continue reading
A Conversation with FDA/DDMAC About Pharma, Social Media and Web 2.0
At the bottom of this posting is a podcast with the FDA on Web 2.0 and pharma, making it an important posting for anyone connected with communications by pharmaceutical companies – advertisers, regulatory and legal departments and marketing whether in … Continue reading
Posted in FDA Policy, New and Social Media, Podcast
18 Comments
J&J and Social Media – How’d They Do It? A Conversation with J&J
Johnson & Johnson has gone far in establishing a digital footprint that has both breadth and depth to it. The company's YouTube channel now has over 90 videos – not branded, but patient educational. That is more than SanofiPasteurTV, GSKVision … Continue reading
Posted in New and Social Media, Podcast
9 Comments
What Would Congress Do? – A Conversation With Dick Gephardt
There is a lot of change going on. Driving past the mall today, one could see lines of tents being erected on the mall. I recently took a photo while walking past the Capitol of the scaffolding as it was … Continue reading
Posted in Podcast
Comments Off on What Would Congress Do? – A Conversation With Dick Gephardt
Weekly Roundup – 09-12/08
Well, Congress is back. You may be relieved that your representation is back at the seat of government, doing that voodoo that they do so well. For me, it means a longer commute and more bad drivers on the road. … Continue reading
Posted in Podcast, Weekly Roundup
Comments Off on Weekly Roundup – 09-12/08